Clinical trials: Pancreas
Cystic Fibrosis
PEP and OPEP Devices in Cystic Fibrosis
Cystic fibrosis (CF) is the most common severe autosomal recessive genetic disease in Caucasians. The CFTR (cystic fibrosis transmembrane regulator) gene, which encodes the chloride channel of the epithelial cell membrane, is…
- Trial name
- NCT05801952
- Testing
- Aerobika* OPEP, PARI O-PEP (Flutter), PARI PEP® S System
- Where
- Poland
- Volunteers
- 60 people
- Sponsor
- National Institute for Tuberculosis and Lung Diseases, Poland
Pancreatic Neoplasms
Contrast-enhanced Diffusion-weighted MRI to Detect Liver Metastases in Patients With Pancreatic Cancer
Given the dismal prognosis of pancreatic cancer, detecting liver metastases early can avoid inappropriate therapy with the associated substantial risks, long-term hospital admissions and high costs, but without survival benefit.
- Trial name
- DIA-PANC (NCT03469726)
- Testing
- Contrast-enhanced Diffusion-weighted MRI
- Where
- 7 sites in Greece, Netherlands and 2 more
- Volunteers
- 465 people
- Sponsor
- Radboud University Medical Center
Solid Tumors (Pancreatic Cancer, Esophageal Cancer, Gastric Cancer, Cholangiocarcinoma, Lung Cancer and Ovarian Cancer)
An Exploratory Clinical Study to Evaluate the Safety and Efficacy of NK Cells (Combined With Standard Therapy) in the Treatment of Solid Tumor Patients
An exploratory clinical study to evaluate the safety and efficacy of NK cells (combined with standard therapy) in the treatment of solid tumor patients
- Trial name
- CCT-ANK-11 (NCT06284226)
- Testing
- Allogeneic NK（CCT-ANK-11)
- Sponsor
- Beijing Kejing Biotechnology Co., Ltd.
Pancreatic Neoplasm, Pituitary Neoplasm
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
This study will assess the effectiveness and safety of pasireotide long-acting release in patients who have rare tumors of neuroendocrine origin.
- Conditions
- Pancreatic Neoplasm, Pituitary Neoplasm, Nelson Syndrome, Ectopic ACTH Syndrome
- Trial name
- NCT00958841
- Testing
- pasireotide LAR
- Where
- 42 sites in United States, Argentina and 10 more
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Cystic Fibrosis
STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)
To evaluate the micro-biologic efficacy and safety of a streamlined treatment for early onset methicillin-resistant staphylococcus aureus (MRSA) in patients with cystic fibrosis.
- Trial name
- STAR-TER (NCT03489629)
- Testing
- Trimethoprim Sulfamethoxazole (TMP/SMX), Minocycline, Mupirocin
- Where
- 9 sites in United States
- Volunteers
- 49 people
- Sponsor
- University of North Carolina, Chapel Hill
Diabetes Mellitus, Type 2, Exocrine Pancreatic Insufficiency
A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEI
This study is a 2-part open-label, randomized, crossover, multicenter, non-therapeutic Phase II study to investigate the presence of pancreatic exocrine insufficiency (PEI) in patients with Type 2 diabetes mellitus (T2DM), and to…
- Trial name
- PRECISE (NCT02370537)
- Testing
- Epanova® (omega-3 carboxylic acids), Omacor® (omega-3-acid ethyl esters)
- Where
- 22 sites in Denmark, Hungary and 4 more
- Volunteers
- 490 people
- Sponsor
- AstraZeneca
Inflammatory Bowel Disease, Ulcerative Colitis
Efficacy of Energy Therapy in the Management of Chronic Pain Medical Condition in Children and Adolescents.
Paediatric and adolescent patients with chronic pain associated with their medical condition will be invited to participate in this study.
- Conditions
- Inflammatory Bowel Disease, Ulcerative Colitis, Crohn Disease, Chronic Pancreatitis
- Trial name
- ET&CP (NCT05394272)
- Testing
- Energy Therapy - Pranic Healing
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- King's College Hospital NHS Trust
Coronary Artery Disease, Congestive Heart Failure
Prognostic Indicators as Provided by the EPIC ClearView
The objective of this study is to determine whether the finger tip images captured by the EPIC ClearView device, when analyzed via the ClearView software, produce a Response Scale that characterizes trends consistent with known…
- Conditions
- Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation
- Trial name
- GBMC (NCT01476995)
- Where
- United States
- Volunteers
- 353 people, healthy volunteers welcome
- Sponsor
- Epic Research & Diagnostics, Inc.
Pancreatic Cancer
Chemotherapy for Patients With Locally Advanced Pancreatic Cancer (LAPC) With Additional Chemo-radiotherapy (CRT) for Patients With Borderline Resectable Tumours
Treating patients with initial local non-resectable pancreatic cancer with a combination of oxaliplatin, irinotecan \& 5-FU(FOLFIRINOX), consolidated with chemoradiotherapy in potentially resectable patients, will result in a…
- Trial name
- NCT01397019
- Testing
- Oxaliplatin, irinotecan, 5-FU & leucovorin
- Where
- 3 sites in Denmark
- Volunteers
- 56 people
- Sponsor
- Per Pfeiffer
Cystic Fibrosis
BI 443651 Multiple Rising Dose in Healthy Volunteers Followed by a Cross-over in CF Subjects
The objective of this study is to investigate the safety, tolerability, and pharmacokinetics of BI 443651 in male and female healthy volunteers and subjects with Cystic Fibrosis (CF).
- Trial name
- NCT02976519
- Testing
- BI 443651
- Where
- 5 sites in Germany, United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Islet Cell Adenoma, Neoplasm Metastasis
Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas
Patients with Zollinger-Ellison Syndrome suffer from ulcers of the upper gastrointestinal tract, higher than normal levels of gastric acid, and tumors of the pancreas known as non-beta islet cell tumors.
- Conditions
- Islet Cell Adenoma, Neoplasm Metastasis, Zollinger Ellison Syndrome
- Trial name
- NCT00001165
- Testing
- combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin
- Where
- United States
- Volunteers
- 999 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Cystic Fibrosis
YOGA-CF (Yoga Outcomes Get Assessed in Cystic Fibrosis)
The goal of this clinical trial is to investigate the effects of yoga participation for adults with cystic fibrosis. The main question it aims to answer is: does participation in yoga affect health-related quality of life for…
- Trial name
- YOGA-CF (NCT06120465)
- Testing
- Yoga
- Where
- United Kingdom
- Volunteers
- 314 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Pancreatic Acinar Carcinoma, Pancreatic Neoplasms
Acelarin First Line Randomised Pancreatic Study
The primary purpose of this study is to assess whether Acelarin (NUC-1031) is superior to gemcitabine in terms of overall survival for treatment of patients with metastatic pancreatic carcinoma.
- Trial name
- ACELARATE (NCT03610100)
- Testing
- Acelarin, Gemcitabine
- Where
- United Kingdom
- Volunteers
- 328 people
- Sponsor
- The Clatterbridge Cancer Centre NHS Foundation Trust
Pancreatic Cancer
Predicting Pancreatic Fistula After Pancreatic Surgery Using Preoperative Immunity
The goal of this observational study is to develop and validate a preoperative immunological signature for predicting postoperative pancreatic fistula (POPF) in adult patients undergoing pancreatic surgery for pancreatic cancer.
- Trial name
- NCT07827911
- Testing
- blood sampling
- Where
- France
- Volunteers
- 310 people
- Sponsor
- Institut Paoli-Calmettes
Pancreatic Adenocarcinoma
Reorganization of the Healthcare System During COVID-19 Pandemic: Impact on Management of Patients With Exocrine Pancreatic Cancer
Pancreatic adenocarcinoma will be the 2nd cause of death by cancer in Europe in 2030. Pancreatic adenocarcinoma has poor prognosis with an all-stages combined 5-year survival rate below 8%.
- Trial name
- CAPANCOVID-19 (NCT04406571)
- Testing
- Data record
- Where
- France
- Volunteers
- 700 people
- Sponsor
- CHU de Reims
Acute Pancreatitis (AP)
Heparin to Prevent Organ Failure in Acute Pancreatitis
This clinical trial is designed to evaluate whether adding a standard blood-thinning medication, Unfractionated Heparin, to standard hospital care can help prevent severe organ failure in patients admitted with acute…
- Trial name
- NCT07609771
- Testing
- Unfractionated heparin, Standard supportive care
- Where
- Pakistan
- Volunteers
- 100 people
- Sponsor
- Allied Hospital Faisalabad
Cystic Fibrosis
Longitudinal Analysis of Respiratory and Intestinal Microbiome in Cystic Fibrosis
Respiratory und intestinal microbiome will bei analyzed during a period of 6 months. In a retrospective analysis it will be looked for correlations between microbiome and cf therapy (e.g.
- Trial name
- NCT03335202
- Testing
- analysis of microbiome
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- University of Kiel
Cystic Fibrosis
Anti-IL5 and Other Biotherapies in Cystic Fibrosis
Our project is to describe retrospectively and prospectively CF patients treated with biotherapy in French CF centers. Main objective: To describe the clinical and paraclinical course of CF patients before and after treatment…
- Trial name
- MAB-CF (NCT04256772)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Montpellier
Immune Evasion, Tumor, Pancreas Cancer
Construction and Clinical Application of the Immune Map of Pancreatic Cancer Evolution
The intricate interplay between systemic immunity and tumors profoundly influences not only the onset and progression of tumors but also serves as a crucial window into understanding tumor evolution and treatment status.
- Trial name
- NCT07034339
- Where
- China
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Zhejiang University
Pancreatic Adenocarcinoma
Borderline Resectable or Resectable or Advanced Pancreatic Adenocarcinoma
Observational study of the Clinical Practice in patients with Borderline resectable or resectable or advanced pancreatic adenocarcinoma.
- Trial name
- NCT03266757
- Volunteers
- 200 people
- Sponsor
- Hellenic Society of Medical Oncology